Transplant and Cell Therapies Committee

THURSDAY, OCTOBER 8 • 2:00 – 3:30 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

Agenda

1. Pending Studies

a. A Phase II Randomized Study Comparing Total Marrow and Lymphoid Irradiation (TMLI) with Fractionated Total Body Irradiation (FTBI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) in Patients with Acute Lymphoblastic Leukemia – Dr. Monzr M Al Malki and Dr. Jeffrey Wong

b. EA 4241: A Two Cohort Randomized Study for Patients with High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse – Dr. Sairah Ahmed

2. Active Protocol Updates

a. SWOG 2213: Phase 3 randomized trial of daratumumab, cyclophosphamide, bortezomib and dexamethasone (D-VCD) induction followed by autologous stem cell transplant or D-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis – Dr. Patrick Hagen

b. SWOG 2114: A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma - Dr. Brian Hess

c. EA 4232: PTCL-STAT (Stem-cell Transplant AuTologous) - Dr. Marc Hoffmann

d. MyeloMatch Update: MM3TCT-A03: A Two Cohort, Randomized, Open-Label, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined with Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study. – Dr. Stephanie Tsai